p.frisk

TL2 · Kolkata

Contributes reviews on supplier material. Based in Kolkata.

Joined 31 January 2025 · last posted 1d

77 posts, newest first. Showing up to 150.

Follow-up: How compounding permissions changed when supply normalised Replied, post #78 · Sourcing › Regulatory · 26 Jul 2026 · 3 likes Compounding and pharmacy rules: some jurisdictions allow a pharmacy to compound a drug that is not on the market under specific conditions. The conditions are strict…
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction Replied, post #45 · Compounds › Retatrutide · 24 Jul 2026 · 11 likes Where I part company with post #41, and it is a narrow parting. Renal and cardiovascular outcome data does not exist for this compound. Absence of a reported signal in…
Request: a per-category review queue Replied, post #114 · Meta › Feature requests · 19 Jul 2026 · 18 likes The documentation on per-category review queue is better than this thread and I say that as someone who has posted in the thread.
Coming back to: Where the four-week escalation interval comes from, and what it is not Replied, post #27 · Practice › Dosing & titration · 14 Jul 2026 · 15 likes Adding the measurement that post #26 says would settle it. The four-week escalation interval is a convention from the pivotal trials, not a pharmacological constant.…
Athletes in weight-category sports: a different risk calculus Replied, post #20 · Clinical › Special populations · 10 Jul 2026 · 0 likes Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is…
The anatomy of a question that gets answered within an hour — does this still hold? Replied, post #8 · Start Here › How to Ask · 9 Jul 2026 · 31 likes I read post #6 twice before replying, because I had assumed the opposite. A question about somebody else's post should be a reply to that post, not a new topic. A…
Second pass at: Sleep apnoea improving and the equipment implications Replied, post #78 · Wellbeing › Sleep · 6 Jul 2026 · 2 likes Stimulants and sleep: if supplementing with caffeine or other stimulants for energy during weight loss, timing and dose matter for sleep. Evening stimulant use…
Semaglutide and alcohol: what is actually documented Replied, post #14 · Compounds › Semaglutide · 5 Jul 2026 · 9 likes Semaglutide versus liraglutide in STEP 8: semaglutide produced greater weight reduction and the discontinuation rates differed. But the trial was open-label for the…
CJC-1295 with and without DAC: what the modification does Replied, post #102 · Compounds › Secretagogues & GH axis · 4 Jul 2026 · 22 likes Injection-site reactions are reported more often in this family than for the incretins. Whether that is the compounds or the preparations they are typically supplied in…
Review: a draft on reconstitution arithmetic, with objections — what changed since Replied, post #31 · Documentation › Doc review · 27 Jun 2026 · 4 likes Reading back through, this was answered upthread and I missed it. My fault.
Insurance and replacement policies, compared Replied, post #29 · Sourcing › Logistics · 19 Jun 2026 · 6 likes Picking up post #28: that is the part I would want checked first. Insurance and replacement policies came up in a thread eighteen months ago and was answered well. I…
Carryover and the ghost peak from last week's standard — what changed since Replied, post #32 · Analytics › HPLC & UHPLC · 14 Jun 2026 · 0 likes Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a…
Why 99.2% and 97.8% on the same lot can both be correct Replied, post #10 · Analytics › HPLC & UHPLC · 13 Jun 2026 · 4 likes I changed my mind about 99.2% and 97.8% after someone here asked me for the source and I could not produce one. That is worth saying out loud because it is the ordinary…
Blinding yourself: practical methods and their limits Replied, post #33 · Research Methods › N-of-1 designs · 11 Jun 2026 · 26 likes Blinding yourself is well covered in the tag pages, and the older discussions are better than the recent ones because they were argued out properly. Worth twenty…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #57 · Outcomes › Progress reports · 9 Jun 2026 · 15 likes Picking up post #56: that is the part I would want checked first. Maintenance series are the ones this subcategory needs most and receives least. The interesting…
How shortages have affected compounding permissions — does this still hold? Replied, post #8 · Access › Shortages · 1 Jun 2026 · 0 likes I had written a reply contradicting post #7 and deleted it. Here is what survived. Compounding during shortages: some jurisdictions allow pharmacy compounding when a…
Alcohol: what is documented and what is folklore Replied, post #28 · Practice › Interactions · 26 May 2026 · 1 like Post #25 describes the usual case. This is about the unusual one. My understanding of alcohol is a few years old and may have been superseded. If it has been, I would…
Follow-up: Search filters: what is missing Replied, post #109 · Meta › Site feedback · 23 May 2026 · 3 likes Something worth flagging about Search filters: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern and not a…
How much fluid is actually needed, and how you would know Replied, post #5 · Nutrition & Training › Hydration & electrolytes · 12 May 2026 · 3 likes Noted, and thank you for writing it out rather than summarising it.
Search filters: what is missing Replied, post #53 · Meta › Site feedback · 3 May 2026 · 9 likes That is a cleaner way of putting what I was circling around.
Rotating between abdomen, thigh and upper arm: absorption differences — one year on Replied, post #53 · Practice › Administration · 26 Apr 2026 · 13 likes Since Rotating between abdomen keeps coming up, it should probably be a maintained page rather than a recurring thread. I am happy to draft it if someone with more…
Converting between mg/mL and units per dose, both directions — the long version Replied, post #82 · Practice › Reconstitution · 23 Apr 2026 · 9 likes Dead volume is the part nobody mentions until it costs them a dose. A fixed-needle insulin syringe holds very little; a detachable-needle luer configuration can hold…
Injection discomfort: needle gauge, volume, temperature, technique Replied, post #49 · Practice › Administration · 9 Apr 2026 · 18 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
The headache that turns out to be dehydration — the long version Replied, post #18 · Nutrition & Training › Hydration & electrolytes · 6 Apr 2026 · 27 likes Headache is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which one is…
Revisiting: Absolute versus relative contraindications Replied, post #57 · Safety › Contraindications · 2 Apr 2026 · 0 likes Research-use-only material has no labelling and therefore no contraindications listed, which is not the same as having none. That distinction has done more work for me…
A single out-of-range value on an otherwise normal panel Replied, post #26 · Clinical › Bloodwork · 23 Mar 2026 · 17 likes Glycaemic markers integrate over different periods. A point glucose and a longer-term marker disagreeing is not a contradiction; it is two different questions. Happy to…
Why the absence of controlled human data on BPC-157 matters more than people admit Replied, post #3 · Compounds › Repair & healing peptides · 22 Mar 2026 · 2 likes Reported local reactions are common enough in first-hand accounts here to be worth mentioning and are not characterised in any published series.
Amylin receptor signalling and satiety — what changed since Replied, post #44 · Pharmacology › Receptor biology · 13 Mar 2026 · 0 likes In vitro potency and clinical potency are related by a long chain of assumptions. A compound more potent at the receptor is not necessarily more effective at a…
Introducing myself: pharmacist, sceptic, reluctant participant — one year on Replied, post #49 · Lounge › Introductions · 12 Mar 2026 · 17 likes Welcome aboard. If you post an introduction and then nothing for a month, nobody notices and nobody minds. Come back when there is something you want to know. This has…
Coming back to: Washout: how long is long enough, and for what purpose Replied, post #66 · Pharmacology › Pharmacokinetics · 10 Mar 2026 · 27 likes Where two sources give different half-lives, check the study design before deciding either is wrong. Sampling duration, assay sensitivity and population all move the…
Reused chromatograms across lots: how to spot it — what changed since Replied, post #22 · Analytics › COA interpretation · 7 Mar 2026 · 25 likes Confirming post #19 from a second method, which matters more than confirming it from a second person. The distinction between release testing and characterisation is…
Second pass at: Identical chromatograms across two different lots Replied, post #39 · Sourcing › Red flags · 3 Mar 2026 · 0 likes Post #36 put the caveat in the right place and I want to underline it. Where somebody posts a concern, ask what would resolve it before arguing about it. Half of these…
Revisiting: Language barriers in accessing a prescription abroad Replied, post #137 · Access › International · 1 Mar 2026 · 16 likes Adding the measurement that post #134 says would settle it. Regional practice around what a pharmacy will and will not do varies enormously and is not deducible from…
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #58 · Analytics › Impurities & related substances · 18 Feb 2026 · 32 likes Something worth flagging about rising related-substance: the strongest-sounding claims in this thread are the ones with no source attached, which is the usual pattern…
Forced degradation studies: designing one that is informative Replied, post #7 · Analytics › Method validation · 15 Feb 2026 · 0 likes Confirming post #4 from a second method, which matters more than confirming it from a second person. Before the thread moves on from forced degradation studies — what…
Second pass at: The topic list is dense — is that deliberate? Replied, post #71 · Meta › Site feedback · 14 Feb 2026 · 0 likes Following this. I have the same question and no better information than the first post.
Tag proliferation and whether we should prune — what changed since Replied, post #7 · Meta › Site feedback · 3 Feb 2026 · 15 likes Moderation decisions: if you disagree with a moderation decision, raising it here gives it visibility. Staff will reconsider if you make a substantive case. For what it…
Trifluoroacetate content and its consequences Replied, post #59 · Analytics › Impurities & related substances · 1 Feb 2026 · 0 likes Marking my place. If it changes for me I will come back and say so.
Reference intervals: how they are constructed and why one in twenty flags Replied, post #43 · Clinical › Bloodwork · 30 Jan 2026 · 3 likes Two claims get bundled together under reference intervals and they need separating. The descriptive one — this is what was observed — is usually well supported. The…
Aggregates and why a purity assay may miss them entirely Replied, post #7 · Analytics › Impurities & related substances · 13 Dec 2025 · 13 likes Everything in post #5 holds. The case it does not cover is the one I have. Aggregates may be a multiple of the monomer mass and may not elute at all under a standard…
[2026 update] Does a peptide degrade silently, with no visual change? Replied, post #4 · Practice › Storage & stability · 12 Dec 2025 · 1 like I had written a reply contradicting post #2 and deleted it. Here is what survived. The failure mode on peptide is boring rather than dramatic. It is almost always the…
Promotion criteria, and the one that stops most nominations — the long version Replied, post #106 · Documentation › Doc review · 5 Dec 2025 · 21 likes One more thing on Promotion criteria that took me far too long to see: the two figures people quote are not measuring the same quantity. Once you notice that, the…
[2026 update] What steady state means for the decision to escalate Replied, post #73 · Practice › Dosing & titration · 12 Nov 2025 · 17 likes The practical version of steady state is three sentences long. The rigorous version is three pages and reaches the same conclusion with the conditions attached.
Documentation that appears only after payment Replied, post #72 · Sourcing › Red flags · 9 Nov 2025 · 6 likes I had written a reply contradicting post #70 and deleted it. Here is what survived. Checked the documentation claim against the primary source this morning. It…
Reading SURMOUNT-1 without the press release Replied, post #20 · Compounds › Tirzepatide · 29 Sep 2025 · 5 likes The arithmetic in post #18 is right; the assumption feeding it is the part to check. The apnoea-hypopnoea index used in SURMOUNT-OSA is an objective measurement rather…
Reading an interaction checker output critically Replied, post #5 · Practice › Interactions · 13 Sep 2025 · 7 likes I think the reading an interaction checker output question is answerable and has not been answered, which is a more optimistic position than most of this thread.
Second pass at: Why this subcategory is stricter about sourcing than most Replied, post #89 · Compounds › Secretagogues & GH axis · 22 Aug 2025 · 0 likes Effects reported at the level of appetite are the most consistently described and the most mechanistically direct for the ghrelin-receptor compounds, which is not what…
Follow-up: Why the titration planner refuses to produce a schedule below a floor Replied, post #90 · Data & Tools › Calculators · 21 Aug 2025 · 29 likes Acknowledging rather than arguing. The reasoning holds as far as I can follow it.
[2026 update] Journal club: is percentage weight change the right endpoint? Replied, post #68 · Evidence › Journal club · 19 Aug 2025 · 0 likes The baseline characteristics table is the single most useful page for the questions that get asked here, because it tells you who the result applies to. Reading it…
Why a pen's dose steps are fixed and what that costs you — one year on Replied, post #28 · Devices › Pens & autoinjectors · 4 Aug 2025 · 13 likes Everything in post #26 holds. The case it does not cover is the one I have. Needle changes between doses are specified for a reason and the reasons are dose accuracy…
TB-500 and thymosin beta-4: the fragment versus the protein Replied, post #90 · Compounds › Repair & healing peptides · 3 Aug 2025 · 0 likes Building on post #87 rather than restating it. Filing a mild objection to the consensus on TB-500 and thymosin beta-4. Mild because I might be wrong; an objection…
Publishing an inconvenient result: a case study Replied, post #53 · Sourcing › Independent verification · 22 Jul 2025 · 19 likes Post #51 put the caveat in the right place and I want to underline it. A record with four results over sixteen months is a thin record rather than a bad one, and the…
A field-by-field walk through a certificate of analysis Replied, post #79 · Analytics › COA interpretation · 16 Jul 2025 · 18 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Pregnancy as an absolute contraindication Replied, post #15 · Safety › Contraindications · 17 May 2025 · 17 likes Post #12 is right about the mechanism and I think understates the practical bit. The confident answers on pregnancy and the well-sourced answers are not the same…
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #115 · Compounds › Cagrilintide & amylin analogues · 14 May 2025 · 19 likes Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly…
Coverage for the indication versus for the drug Replied, post #33 · Access › Insurance & coverage · 18 Apr 2025 · 11 likes Formulary status: the list of covered medications and the tier (how much you pay) they are on. Checking the current formulary before going to a clinic appointment saves…
A well-designed study with a badly written abstract Replied, post #19 · Evidence › Study critique · 11 Apr 2025 · 1 like Statistical significance and clinical importance are different and both are needed. A significant difference below the minimal important difference is a real finding of…
Why cagrilintide alone is discussed so much less than in combination Replied, post #40 · Compounds › Cagrilintide & amylin analogues · 27 Mar 2025 · 16 likes The dosing interval: cagrilintide's half-life is roughly 7 to 8 days, suitable for weekly dosing. The pharmacokinetics are the reason the dosing schedule makes sense.
One lot is one lot: when a report becomes a pattern — the long version Replied, post #105 · Sourcing › Vendor reports · 18 Mar 2025 · 4 likes Fair, and the limits you put on it are the part I will remember.
Consistent declarations and why they matter more than clever ones Replied, post #74 · Sourcing › Logistics · 23 Feb 2025 · 3 likes Split shipments reduce single-point risk and increase the number of transits. Which trade is right depends on what you are protecting against. It is worth checking…
Why mass spectrometry cannot tell you about an epimer Replied, post #65 · Analytics › Mass spectrometry · 21 Feb 2025 · 31 likes Common adducts: sodium adds ≈22, potassium adds ≈38 compared to hydrogen. A [M+Na]+ peak is common and its mass is predictable from the base mass. It is a small point…
Assessing a warm arrival: the decision process Replied, post #2 · Sourcing › Logistics · 11 Feb 2025 · 18 likes The honest answer on assessing a warm arrival is that it depends, and the useful part is the list of what it depends on. Four items, in rough order of how much they…
Distinguishing a deletion sequence by mass alone — the long version Replied, post #3 · Analytics › Mass spectrometry · 2 Feb 2025 · 31 likes Building on post #2 rather than restating it. Purity and identity are different questions: LC-MS establishes that the species at a retention time has the expected mass.…
A promotion I argued against, and why I lost Replied, post #83 · Documentation › Doc review · 2 Feb 2025 · 4 likes The useful distinction on promotion is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has error bars.
What SELECT changed about how semaglutide is discussed, and what it did not Started this topic · Compounds › Semaglutide · 29 Jan 2025 · 37 likes Asking directly, because I could not find a straight answer: What SELECT changed about how semaglutide is discussed, and what it did not I was wrong about SELECT in a…
Reading a supplementary appendix and finding the interesting part Replied, post #78 · Evidence › Trials · 28 Jan 2025 · 14 likes Reading the supplementary appendix is where most of the real information is, and it is where almost nobody goes. The baseline table alone answers half the…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #94 · Evidence › Journal club · 16 Jan 2025 · 11 likes Sessions on negative or null results are consistently the most instructive and the hardest to get anyone to attend.
Revisiting: What a well-designed human trial of a secretagogue would look like Replied, post #30 · Compounds › Secretagogues & GH axis · 13 Jan 2025 · 0 likes I would keep well-designed human trial and the decision it usually gets used for separate in this thread. They are related and they are not the same question, and…
Follow-up: Individual participant data versus aggregate data Replied, post #62 · Evidence › Meta-analyses · 10 Jan 2025 · 6 likes Individual participant data pooling is a much stronger design than aggregate pooling and is rare because it requires cooperation rather than a search.
Oral semaglutide bioavailability and its variability between people — a second dataset Replied, post #141 · Compounds › Oral incretins · 29 Dec 2024 · 19 likes This follows post #138 rather than contradicting it. A methods point on Oral semaglutide bioavailability rather than a substantive one: if the comparison is not like…
Follow-up: Tirzepatide's shorter half-life and its one practical consequence Replied, post #65 · Compounds › Tirzepatide · 2 Dec 2024 · 2 likes Where I part company with post #61, and it is a narrow parting. On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently…
EMA product information as a primary source — does this still hold? Replied, post #101 · Regional › European Union · 17 Nov 2024 · 9 likes A device-and-compound combination has one authorisation and two supply chains, and the device is more often the limiting one. That matches what I was told, which is not…
Why "any advice?" is the least effective ending for a post Replied, post #29 · Start Here › How to Ask · 12 Nov 2024 · 3 likes Reading back through, this was answered upthread and I missed it. My fault.
When to suspect the method rather than the sample Replied, post #21 · Analytics › Method validation · 8 Oct 2024 · 0 likes Post #18 is the version of this I will quote in future. One addition. Linearity across the working range is a routine demonstration and it constrains how far a result…
Revisiting: Melanocortin agonists: mechanism and the documented adverse profile Replied, post #33 · Compounds › Other compounds · 5 Oct 2024 · 24 likes The strongest argument against my own position on Melanocortin agonists, stated as well as I can state it, since nobody else has yet.
Type 2 diabetes and the largest part of the evidence base — does this still hold? Replied, post #12 · Clinical › Comorbidities · 1 Oct 2024 · 11 likes Marking my uncertainty on Type 2 diabetes explicitly. I am confident about the direction, much less confident about the size, and not confident at all that it…
Tracking a preprint to publication: a worked example — the long version Replied, post #39 · Evidence › Preprints · 19 Sep 2024 · 26 likes Useful. I have added it to my own notes with the date on it.